DCVAC/LuCa

Background Our study was the first clinical trial showing the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with chemo in Chinese NSCLC patients (Zhong R, Ling X, et al...Patients were treated with carboplatin/pemetrexed for up to 6 cycles, followed by pemetrexed maintenance for up to 21 cycles...Conclusions The combination of DCVAC/LuCa and chemo continued to provide long-term benefits as a first-line treatment in Chinese patients with stage IV, non-squamous NSCLC without EGFR/ALK aberrations. The long-term benefits and the good safety profile support the conduct of a validation trial in a larger population with greater diversity.

DCVAC/LuCa, combined with standard of care chemotherapy and Shenqi Fuzheng injection exhibited good benefit in Chinese patients with recurrent metastatic or advanced (stage IIIB/IV) NSCLC, and also significantly improved Qi insufficiency constitution. There were no related adverse events with DCVAC/LuCa treatment.

DCVAC/LuCa, combined with standard chemotherapy and TCM had exhibited the potential to improve the survival in patients with advanced NSCLC, and decrease the occurrence of adverse events. But the sample size of this study is small, a further clinical investigation is needed. Research Funding: SOTIO